The city based Bharat Biotech International Limited (BBIL) has developed the Hepatitis 'B' vaccine Revac-B without using heavy metals. It had been focussing on developing vaccines and other bio-pharmaceuticals based on recombinant DNA technology for the past three years.

Stating this to mediapersons, here today, Dr. Krishna Ella, Managing Director of BBIL said that the company is promoted by Internationally reputed Academicians, Scientists, Clinicians and Technologists to provide quality health care products that are highly cost effective.

The company has been actively engaged in cloning, sequencing, process optimization, down stream processing and formulation of various bio molecules since 1997. He said the BBIL production facility is equipped with state-of-the-art technology, and it is the largest Hepatitis B vaccine production unit in the entire Asian and Pacific region with a capacity of over 100 million doses per annum.

Dr Ella said that the company was striving relentlessly for creating a healthier tomorrow through pioneering research.

He said that the company is also developing vascular endothelial growth factor a drug indicated for cascualr angio-genesis in collaboration with Centre for Biological Technology, New Delhi.

The company also received the country's prestigious award from the Department of Scientific and Industrial Research of India for its best Research and Development efforts for the year 1999, he said.